ArticleCureus2022
Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Pooled it
- New-onset or flare-up of bullous pemphigoid associated with COVID-19 vaccines: a systematic review of case report and case series studies.Frontiers in medicine · 2024Pooled it
- A case of cutaneous small vessel vasculitis after the seventh dose of COVID-19 vaccination.Journal of general and family medicine · 2025Article
- New-onset bullous pemphigoid following the fifth dose of the COVID-19 vaccine Pfizer-BioNTech: A case report.SAGE open medical case reports · 2025Article
- A Comprehensive Review on the Intricate Interplay between COVID-19 Immunization and the New Onset of Pemphigus Foliaceus.Vaccines · 2024Review
- New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.Vaccines · 2024Review
- Pemphigus vulgaris after the second dose of COVID-19 vaccination: a case report.Journal of medical case reports · 2023Article
- Review
- Mucous Membrane Pemphigoid Following the Administration of COVID-19 Vaccine.Head and neck pathology · 2023Article
- Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.Frontiers in medicine · 2023Review
- Pemphigus Foliaceus after COVID-19 Vaccination: A Report of Two Cases.Case reports in dermatological medicine · 2023Article
- Corona Virus Disease-19 Vaccine-associated Autoimmune Disorders.Rheumatology and immunology research · 2022Review
- Article
- Pemphigus during the COVID-19 Epidemic: Infection Risk, Vaccine Responses and Management Strategies.Journal of clinical medicine · 2022Review
- Pseudo-Pemphigoid Gestationis Eruption Following SARS-CoV-2 Vaccination with mRNA Vaccine.Dermatopathology (Basel, Switzerland) · 2022Article
- The multifactorial complexities of autoimmune development in Pemphigus vulgaris: Critical evaluation of the role of environmental and lifestyle "exposome" factors.Frontiers in immunology · 2022Review
- Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature.Clinical, cosmetic and investigational dermatology · 2022Review
- Severe aggravation and possible triggering of pemphigus vulgaris following COVID-19 vaccination: report of two cases.Anais brasileiros de dermatologiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune bullous diseases (AIBDs) are a heterogeneous group of diseases characterized by cutaneous and mucosal vesicles, blisters, and erosions. Several factors can trigger this disease, including vaccines; but this entity remains very rare. We hypothesized that vaccination against coronavirus disease 2019 (COVID-19) could trigger an immunological response in genetically predisposed individuals. We report five cases of new-onset autoimmune bullous diseases triggered by the COVID-19 vaccine. Clinical and histopathological examinations confirmed the diagnosis of bullous pemphigoid (BP) in three patients and pemphigus in the other two. According to the French method of imputability, the pharmacovigilance investigation showed an I5B4 causality assessment score for the vaccines, interpreted as highly probable, for all the patients. The diagnosis of vaccine-induced autoimmune bullous dermatosis was highly suspected. One patient's condition improved by dermocorticoids alone, while the other four required oral corticosteroid therapy at 0.5 mg/kg/day, which led to a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.